Abstract
Patients with nephrotic syndrome are at increased risk for thromboembolic events such as deep venous and arterial thrombosis, renal vein thrombosis and pulmonary embolism. This thrombophilic phenomenon has been attributed to a “hypercoagulable” state in which an imbalance between naturally occurring pro-coagulant/pro-thrombotic factors and anti-coagulant/antithrombotic factors promotes in situ thrombosis in deep veins or arteries. Management of thromboembolic events may be divided in prophylactic and therapeutic strategies. Hypoalbuminemia is the most significant independent predictor factor of thrombotic risk, especially for values <2 g/dL. However, the most important question in these patients is whether to anticoagulate prophylactically or not. The decision depends on type of glomerulonephritis, proteinuria severity, other predisposing factors and prior history of thrombosis. Reviewing the recent literature, we suggest the best therapeutic management of anticoagulation for patients with nephrotic syndrome, focusing on prophylactic strategies.
Keywords: Arterial thrombosis, deep venous thrombosis, nephrotic syndrome, proteinuria, renal venous thrombosis, venous thromboembolism.
Current Vascular Pharmacology
Title:Hypercoagulability and Nephrotic Syndrome
Volume: 12 Issue: 3
Author(s): Antonietta Gigante, Biagio Barbano, Liborio Sardo, Paola Martina, Maria L. Gasperini, Raffaella Labbadia, Marta Liberatori, Antonio Amoroso and Rosario Cianci
Affiliation:
Keywords: Arterial thrombosis, deep venous thrombosis, nephrotic syndrome, proteinuria, renal venous thrombosis, venous thromboembolism.
Abstract: Patients with nephrotic syndrome are at increased risk for thromboembolic events such as deep venous and arterial thrombosis, renal vein thrombosis and pulmonary embolism. This thrombophilic phenomenon has been attributed to a “hypercoagulable” state in which an imbalance between naturally occurring pro-coagulant/pro-thrombotic factors and anti-coagulant/antithrombotic factors promotes in situ thrombosis in deep veins or arteries. Management of thromboembolic events may be divided in prophylactic and therapeutic strategies. Hypoalbuminemia is the most significant independent predictor factor of thrombotic risk, especially for values <2 g/dL. However, the most important question in these patients is whether to anticoagulate prophylactically or not. The decision depends on type of glomerulonephritis, proteinuria severity, other predisposing factors and prior history of thrombosis. Reviewing the recent literature, we suggest the best therapeutic management of anticoagulation for patients with nephrotic syndrome, focusing on prophylactic strategies.
Export Options
About this article
Cite this article as:
Gigante Antonietta, Barbano Biagio, Sardo Liborio, Martina Paola, Gasperini L. Maria, Labbadia Raffaella, Liberatori Marta, Amoroso Antonio and Cianci Rosario, Hypercoagulability and Nephrotic Syndrome, Current Vascular Pharmacology 2014; 12 (3) . https://dx.doi.org/10.2174/157016111203140518172048
DOI https://dx.doi.org/10.2174/157016111203140518172048 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacological Characteristics and Clinical Applications of K201
Current Clinical Pharmacology “Seeing is Believing”: Perspectives of Applying Imaging Technology in Discovery Toxicology
Combinatorial Chemistry & High Throughput Screening Interleukin-1 and Occlusive Arterial Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Molecular Targets and Natural Compounds in Drug Development for the Treatment of Inflammatory Pain
Current Drug Targets Vitamin D and Sepsis: From Associations to Causal Connections
Inflammation & Allergy - Drug Targets (Discontinued) Mannose Binding Lectin: A Potential Biomarker for Many Human Diseases
Current Medicinal Chemistry Fenofibrate and Metabolic Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets A Review on Biological Activities and Chemical Synthesis of Hydrazide Derivatives
Current Medicinal Chemistry Vascular Disease and Risk Factors in Chronic Kidney Disease
Vascular Disease Prevention (Discontinued) Pharmacological Inhibition of Protein Tyrosine Phosphatase 1B: A Promising Strategy for the Treatment of Obesity and Type 2 Diabetes Mellitus
Current Medicinal Chemistry Duration of Dual Antiplatelet Therapy After Coronary Stenting
Current Pharmaceutical Design Investigating Drug-induced Mitochondrial Toxicity: A Biosensor to Increase Drug Safety?
Current Drug Safety Coronary Calcium Risk Score and Cardiovascular Risk
Current Vascular Pharmacology Thiazoles and Thiazolidinones as Antioxidants
Current Medicinal Chemistry Caring for HIV-Infected Patients in the ICU in The Highly Active Antiretroviral Therapy Era
Current HIV Research The Mechanism of Calcitriol in Cancer Prevention and Treatment
Current Medicinal Chemistry Innate Immune Inflammatory Response in the Acutely Ischemic Myocardium
Medicinal Chemistry Atherosclerosis-Related Functions of C-Reactive Protein
Cardiovascular & Hematological Disorders-Drug Targets The Emerging Role of Arginase in Endothelial Dysfunction in Diabetes
Current Vascular Pharmacology Obesity Pharmacotherapy: Current Perspectives and Future Directions
Current Cardiology Reviews